Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Columbia University
IGM Biosciences, Inc.
National Institutes of Health Clinical Center (CC)
Celgene